



**DukeNUS**  
Medical School



Centre of  
Regulatory Excellence

## **GRADUATE CERTIFICATE IN PHARMACEUTICAL REGULATION**

### **GMS5003: Fundamentals of Health Products Regulation**

*15 – 19 September 2025*

**Venue:** Training Room 5C (Level 5), Duke-NUS Medical School, 8 College Rd, Singapore 169857

### **WORKSHOP PROGRAMME**

---

#### **Learning outcomes**

- Explain the foundational basis of regulatory management and decision-making for health products
- Explain the essential principles in managing pharmaceuticals across their life cycles
- Describe the regulatory requirements for the different product development phases
- Relate to the real-life settings in regulatory decision-making through hands-on practical sessions
- Recognize the major regulatory organisations steering the innovation of regulatory processes and focus

## Graduate Certificate in Pharmaceutical Regulation

### GMS5003: Fundamentals of Health Products Regulation

**15 – 19 September 2025**

#### Day 1 – 15 September 2025, Mon

| Topic  |  | Speaker/ Organisation  |
|--|--|--|
| 8.30 am  | <b>Welcome Graduate Certificate Students</b>   | <b>Professor John C W Lim</b><br>Executive Director<br>Centre of Regulatory Excellence (CoRE)<br>Duke-NUS Medical School |
| 9.00 am  | <b>Workshop Briefing</b>   | <b>Dr Rathi Saravanan</b><br>Lead Education Associate<br>CoRE, Duke-NUS Medical School                                   |
| 9.15 am  | <b>Brightspace and Assessment Familiarization</b>  | <b>Mr. Osman Bin Mohamad</b><br>Senior Education Associate<br>CoRE, Duke-NUS Medical School                              |
| <b>Session 1: Health Products Regulatory Overview and Role of Regulatory Professionals</b> |  |  |
| 9.45 am  | <b>Introduction to pharmaceutical regulation in the context of healthcare in resource endowed and resource constrained settings</b> <ul style="list-style-type: none"> <li>Provide broad overview of how regulations are evolving in the context of changing global landscape</li> </ul>   |  |
| 11.00 am   | <b>Refreshment Break</b>   |  |
| 11.20 am   | <b>To understand the role of regulation – and different approaches to regulation – in each phase of the product lifecycle</b> <ul style="list-style-type: none"> <li>The role of pharmaceutical regulations and its contribution to the healthcare environment</li> </ul>  |  |
| 12.30 pm   | <b>Lunch</b>   |  |
| 1.30 pm  | <b>Role of regulatory professionals</b> <ul style="list-style-type: none"> <li>Role of regulatory professionals</li> <li>Professional development frameworks</li> </ul>  |  |
| 2.15 pm  | <b>Health Products Regulation: Role of stakeholder interactions for effective regulatory decision making</b> <ul style="list-style-type: none"> <li>Pre-consultations in guiding development</li> <li>Importance of stakeholder interactions in ensuring SEQ of pharmaceutical products</li> </ul>                               |  |
| 3.00 pm  | <b>Refreshment Break</b>   |  |
| 3.15 pm  | <b>Target Product Profiling (TPP) in product development</b> <ul style="list-style-type: none"> <li>Use of TPP significance in product development and market entry</li> </ul>   |  |
| 4.15 pm  | <b>Commercialisation strategies for pharmaceutical products</b> <ul style="list-style-type: none"> <li>Regulatory activities in the context of commercialization and ensuring regulatory compliance in tech transfer</li> <li>Assessing the commercial potential of innovations and inventions</li> <li>Case examples</li> </ul> |  |
| 5.20 pm  | <b>Debrief and Announcements</b>   | <b>CoRE Education Team</b>   |
| 5.30pm   | <b>End of Day 1</b>  |  |

## **Day 2 – 16 September 2025, Tue**

|  | Topic   | Speaker/ Organisation  |
|--|---|------------------------|
| <b>Session 3: Ensuring Quality, Safety and Efficacy of Pharmaceutical Products</b> |   |                        |
| <b>8.30 am</b>   | <b>Overview of Chemistry, Manufacturing and Controls</b> <ul style="list-style-type: none"> <li>• Concept of pharmaceutical quality (PQ/CMC)</li> <li>• Importance and impact of pharmaceutical quality on patient safety</li> <li>• Pharmaceutical quality initiatives</li> <li>• Key regulatory guidelines and requirements</li> <li>• General practices in the industry providing quality assurance</li> </ul> |                        |
| <b>9.30 am</b>   | <b>Manufacturing of pharmaceutical products</b> <ul style="list-style-type: none"> <li>• Introduction to regulatory control on quality</li> <li>• Introduction to ICH CTD Module 3 Quality section</li> </ul>   |                        |
| <b>10.30 am</b>  | <b>Refreshment Break</b>  |                        |
| <b>10.45 am</b>  | <b>Good Manufacturing Practices (GMP): Main Concepts</b> <ul style="list-style-type: none"> <li>• Failures in GMP</li> <li>• GMP history</li> <li>• Basic GMP requirements including definition and quality management</li> </ul>   |                        |
| <b>11.30 am</b>  | <b>Overview of non-clinical requirements for pharmaceuticals</b> <ul style="list-style-type: none"> <li>• Types of nonclinical studies</li> <li>• Data for FIH studies</li> </ul>   |                        |
| <b>12.30 pm</b>  | <b>Lunch</b>  |                        |
| <b>1.30 pm</b>   | <b>Overview of Good Clinical Practice (GCP) requirements and clinical trial application (CTA) for pharmaceuticals</b> <ul style="list-style-type: none"> <li>• Principles of GCP</li> <li>• Key GCP guidelines (WHO/ICH/HSA)</li> <li>• CTA vs CTN</li> </ul>   |                        |
| <b>2.00 pm</b>   | <b>Overview of pharmaceuticals clinical development</b> <ul style="list-style-type: none"> <li>• Phases of Clinical Trials</li> <li>• Design of CT: inclusion exclusion criteria, endpoints</li> </ul>  |                        |
| <b>3.00 pm</b>   | <b>Refreshment Break</b>  |                        |
| <b>3.15 pm</b>   | <b>Practicum I</b><br>Clinical development of pharmaceuticals   | <b>Expert Faculty:</b> |
| <b>5.20 pm</b>   | <b>Debrief and Announcements</b>  | CoRE Education Team    |
| <b>5.30 pm</b>   | <b>End of Day 2</b>   |                        |

### Day 3 – 17 September 2025, Wed

|  | Topic   | Speaker/ Organisation |
|--|---|-----------------------|
| 8.30 am  | Individual and Group assessment I   |                       |
| <b>Session 4: Regulatory Processes for Pharmaceutical Products</b> |   |                       |
| 9.30 am  | <b>Market authorisation application (Pharmaceutical Products)</b> <ul style="list-style-type: none"> <li>Requirements for MAA submission and review in select countries</li> <li>ICH CTD submission requirements</li> </ul> |                       |
| 10.30 am   | Refreshment Break   |                       |
| 10.45 am   | <b>Regulatory requirements for regulatory decision making: Benefit-risk analysis</b> <ul style="list-style-type: none"> <li>Benefit-risk assessment for regulatory decision making</li> </ul>                               |                       |
| 12.00 pm   | Lunch   |                       |
| 1.00 pm  | <b>Practicum II</b><br>Benefit-Risk Assessment of Pharmaceutical Products   | Expert Faculty:       |
| 3.30 pm  | Refreshment Break   |                       |
| 3.45 pm  | <b>Good Submission Practices (GSubP) in supporting efficient therapeutics registration in ASEAN</b>   |                       |
| 4.30 pm  | <b>Good Review Practices (GRevP) and Regulatory cooperation</b> <ul style="list-style-type: none"> <li>WHO GRevP guideline</li> <li>Principles of a Good Review</li> <li>Managing the Review</li> </ul>                     |                       |
| 5.20 pm  | Debrief and Announcements   | CoRE Education Team   |
| 5.30pm   | End of Day 3  |                       |

## **Day 4 – 18 September 2025, Thurs**

| Topic  |  | Speaker/ Organisation  |
|--|--|------------------------|
| <b>Session 5: Post-approval processes and product lifecycle management</b> |  |                        |
| <b>8.30 am</b>   | <b>Managing post-approval quality changes</b> <ul style="list-style-type: none"> <li>• Risk based approach to post-approval changes</li> <li>• Reliance practices in post-approval CMC changes</li> </ul>  |                        |
| <b>9.30 am</b>   | <b>GMP compliance, audit and inspections</b>   |                        |
| <b>10.30 am</b>  | <b>Refreshment Break</b>   |                        |
| <b>10.45 am</b>  | <b>Total Product Lifecycle (TPLC) management</b>   |                        |
| <b>12.00 pm</b>  | <b>Lunch</b>   |                        |
| <b>1.00 pm</b>   | <b>Global trends in pharmacovigilance</b>  |                        |
| <b>1.45 pm</b>   | <b>Overview of pharmacovigilance for pharmaceutical products</b> <ul style="list-style-type: none"> <li>• Introduction to pharmacovigilance</li> <li>• Appreciation of the pharmacovigilance framework</li> <li>• Risk management plans and post-marketing activities</li> </ul> |                        |
| <b>2.30 pm</b>   | <b>Practicum III</b><br>Risk management plans for pharmaceutical products  | <b>Expert Faculty:</b> |
| <b>3.00 pm</b>   | <b>Refreshment Break</b>   |                        |
| <b>3.15 pm</b>   | <b>Practicum III</b><br>Continued and Discussions  |                        |
| <b>5.30pm</b>  | <b>End of Day 4</b>  |                        |

## **Day 5 – 19 September 2025, Fri**

|   | <b>Topic</b>   | <b>Speaker/ Organisation</b>   |
|---|--|--|
| 9.00 am   | <b>End-of-Module (EOM) Assessment</b>  | <b>CoRE Education Team</b>   |
| 10.00 am  | <b>Refreshment Break</b>   |  |
| 10.15 am  | <b>Review of EOM Questions</b>   | <b>CoRE Education Team</b>   |
| <b>Session 6: Trends in Health Products Development and Regulations</b> |  |  |
| 11.00 am  | <b>Introduction to Precision Health and Medicine</b> <ul style="list-style-type: none"> <li>• Overview of landscape</li> <li>• National and Regional programs in Precision Medicine</li> </ul>   |  |
| 12.00 pm  | <b>Development and use of standards in supporting product development</b>  |  |
| 12.30 pm  | <b>Lunch</b>   |  |
| 1.30 pm   | <b>Patient engagement, Coalition to Accelerate Patient Engagement in Asia-Pacific (CAPE)</b> <ul style="list-style-type: none"> <li>• Importance of patient involvement</li> <li>• Patient engagement in product lifecycle</li> <li>• Real world examples</li> </ul> |  |
| 2.00 pm   | <b>Gallery Walk: Target Product Profiling</b>  |  |
| 3.00 pm   | <b>Introduction to Healthcare Services Regulation</b> <ul style="list-style-type: none"> <li>• Trending areas in healthcare landscape</li> <li>• Service models and technologies in Gene therapies</li> </ul>  |  |
| 3.45 pm   | <b>Break</b>   |  |
| 4.00 pm   | <b>Reflection and Peer Sharing</b>   | <b>Dr. Rathi Saravanan</b><br>CoRE   |
| 5.15 pm   | <b>Graduate Certificate Workshop Conclusion</b>  | <b>Prof Silke Vogel</b><br>Deputy Director, CoRE<br>Senior Associate Dean<br>Graduate Studies<br>Duke-NUS Medical School |
| 5.30pm  | <b>End of Workshop</b>   |  |